Nifuratel (Magmilor) in trichomonal vaginitis.

Introduced almost a decade ago, Flagyl (Metronidazole) is still the only acceptable systemic therapy available for trichomoniasis. Fortunately, the efficacy of Flagyl has remained at a very high level and there is no evidence that Trichomonas vaginalis has developed, or is developing, any resistance to it. However, there has always been the occasional case in which even very large doses of Flagyl fail to eradicate the trichomonad and there is an obvious place for some other form of systemic therapy. Nifuratel, the subject of this report, is claimed to be such a treatment. Marketed under the name of Magmilor this is a derivative of Nitrofurantoin and is said to provide effective systemic and topical therapy for trichomoniasis, vaginal moniliasis, and vulvovaginitis due to certain bacteria, and also to be active in some urinary tract infections. Adverse side-effects are reported to be very rare. This report is concerned solely with the effect of Magmilor in trichomonal vaginitis, in which condition continental workers have obtained just over 70 per cent. of cures with one course of treatment (Caeira and Dexeus, 1966; Giocoli, Digesu, and Cascella, 1967).